{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Clinical trials", "Drug development", "Macrofilaricide", "Microfilaricide", "Mode of action", "Onchocerciasis", "Preclinical models"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34642800", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "25"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "13"}], "Language": ["eng"], "ELocationID": ["10.1007/s00436-021-07307-4"], "Journal": {"ISSN": "1432-1955", "JournalIssue": {"Volume": "120", "Issue": "12", "PubDate": {"Year": "2021", "Month": "Dec"}}, "Title": "Parasitology research", "ISOAbbreviation": "Parasitol Res"}, "ArticleTitle": "Onchocerciasis drug development: from preclinical models to humans.", "Pagination": {"StartPage": "3939", "EndPage": "3964", "MedlinePgn": "3939-3964"}, "Abstract": {"AbstractText": ["Twenty diseases are recognized as neglected tropical diseases (NTDs) by World Health Assembly resolutions, including human filarial diseases. The end of NTDs is embedded within the Sustainable Development Goals for 2030, under target 3.3. Onchocerciasis afflicts approximately 20.9 million people worldwide with\u2009>\u200990% of those infected residing in Africa. Control programs have made tremendous efforts in the management of onchocerciasis by mass drug administration and aerial larviciding; however, disease elimination is not yet achieved. In the new WHO roadmap, it is recognized that new drugs or drug regimens that kill or permanently sterilize adult filarial worms would significantly improve elimination timelines and accelerate the achievement of the program goal of disease elimination. Drug development is, however, handicapped by high attrition rates, and many promising molecules fail in preclinical development or in subsequent toxicological, safety and efficacy testing; thus, research and development (R&D) costs are, in aggregate, very high. Drug discovery and development for NTDs is largely driven by unmet medical needs put forward by the global health community; the area is underfunded and since no high return on investment is possible, there is no dedicated drug development pipeline for human filariasis. Repurposing existing drugs is one approach to filling the drug development pipeline for human filariasis. The high cost and slow pace of discovery and development of new drugs has led to the repurposing of \"old\" drugs, as this is more cost-effective and allows development timelines to be shortened. However, even if a drug is marketed for a human or veterinary indication, the safety margin and dosing regimen will need to be re-evaluated to determine the risk in humans. Drug repurposing is a promising approach to enlarging the pool of active molecules in the drug development pipeline. Another consideration when providing new treatment options is the use of combinations, which is not addressed in this review. We here summarize recent advances in the late preclinical or early clinical stage in the search for a potent macrofilaricide, including drugs against the nematode and against its endosymbiont, Wolbachia pipientis."], "CopyrightInformation": "\u00a9 2021. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre of Medical Research, Institute of Medical Research and Medicinal Plants Studies (IMPM), P.O. Box13033, Yaound\u00e9, Cameroon."}, {"Identifier": [], "Affiliation": "Drugs for Neglected Diseases Initiative, Chemin Camille-Vidart 15, 1202, Geneva, Switzerland."}], "LastName": "Ngwewondo", "ForeName": "Adela", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Drugs for Neglected Diseases Initiative, Chemin Camille-Vidart 15, 1202, Geneva, Switzerland."}], "LastName": "Scandale", "ForeName": "Ivan", "Initials": "I"}, {"Identifier": ["0000-0002-5351-5812"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Drugs for Neglected Diseases Initiative, Chemin Camille-Vidart 15, 1202, Geneva, Switzerland. sspecht@dndi.org."}], "LastName": "Specht", "ForeName": "Sabine", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Parasitol Res", "NlmUniqueID": "8703571", "ISSNLinking": "0932-0113"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Pharmaceutical Preparations"}], "SupplMeshList": ["Wolbachia pipientis"], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "prevention & control"], "DescriptorName": "Neglected Diseases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Onchocerciasis"}, {"QualifierName": [], "DescriptorName": "Pharmaceutical Preparations"}, {"QualifierName": [], "DescriptorName": "Wolbachia"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, Babalola OE, Alexander ND, Nuhu I, Evans J, Ibrahim UF, Mahmood AO. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993;341(8838):130\u2013134. doi: 10.1016/0140-6736(93)90002-x.", "ArticleIdList": ["10.1016/0140-6736(93)90002-x", "8093742"]}, {"Citation": "Alexander ND, Cousens SN, Yahaya H, Abiose A, Jones BR. Ivermectin dose assessment without weighing scales. Bull World Health Organ. 1993;71(3\u20134):361\u20136.", "ArticleIdList": ["PMC2393495", "8324855"]}, {"Citation": "Ali MM, Mukhtar MM, Baraka OZ, Homeida MM, Kheir MM, Mackenzie CD. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop. 2002;84(1):49\u201353. doi: 10.1016/s0001-706x(02)00117-1.", "ArticleIdList": ["10.1016/s0001-706x(02)00117-1", "12387910"]}, {"Citation": "Aljayyoussi G, Tyrer HE, Ford L, Sjoberg H, Pionnier N, Waterhouse D, Davies J, Gamble J, Metuge H, Cook D, Steven A, Sharma R, Guimaraes AF, Clare RH, Cassidy A, Johnston KL, Myhill L, Hayward L, Wanji S, Turner JD, Taylor MJ, Ward SA. Short-course, high-dose rifampicin achieves Wolbachia depletion predictive of curative outcomes in preclinical models of lymphatic filariasis and onchocerciasis. Sci Rep. 2017;7(1):210. doi: 10.1038/s41598-017-00322-5.", "ArticleIdList": ["10.1038/s41598-017-00322-5", "PMC5428297", "28303006"]}, {"Citation": "An G, Murry DJ, Gajurel K, Bach T, Deye G, Stebounova LV, Codd EE, Horton J, Gonzalez AE, Garcia HH, Ince D, Hodgson-Zingman D, Nomicos EYH, Conrad T, Kennedy J, Jones W, Gilman RH, Winokur P. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose escalation study. Antimicrob Agents Chemother. 2019;63(4):e02255\u2013e2318. doi: 10.1128/AAC.02255-18.", "ArticleIdList": ["10.1128/AAC.02255-18", "PMC6437481", "30745383"]}, {"Citation": "Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol. 1985;79(1):63\u201378.", "ArticleIdList": ["3838638"]}, {"Citation": "Awadzi K, Dadzie KY, Schulz-Key H, Gilles HM, Fulford AJ, Aziz MA. The chemo therapy of onchocerciasis. XI. A double-blind comparative study of ivermectin, diethylcarbamazine and placebo in human onchocerciasis in northern Ghana. Ann Trop Med Parasitol. 1986;80(4):433\u201342. doi: 10.1080/00034983.1986.11812044.", "ArticleIdList": ["10.1080/00034983.1986.11812044", "3539046"]}, {"Citation": "Awadzi K, Dadzie KY, Kl\u00e4ger S, Gilles HM. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control. Trop Med Parasitol. 1989;40(3):361\u20136.", "ArticleIdList": ["2694315"]}, {"Citation": "Awadzi K, Opoku NO, Addy ET, Quartey BT. The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 1995;46(2):131\u20137.", "ArticleIdList": ["8525285"]}, {"Citation": "Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT. The effects of high-dose iver mectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg. 1999;93(2):189\u2013194. doi: 10.1016/s0035-9203(99)90305-x.", "ArticleIdList": ["10.1016/s0035-9203(99)90305-x", "10450448"]}, {"Citation": "Awadzi K, Gilles HM. Diethylcarbamazine in the treatment of patients with onchocerciasis. BrJ Clin Pharmacol. 1992;34(4):281\u2013288. doi: 10.1111/j.1365-2125.1992.tb05632.x.", "ArticleIdList": ["10.1111/j.1365-2125.1992.tb05632.x", "PMC1381407", "1457260"]}, {"Citation": "Awadzi K, Attah SK, Addy ET, Opoku NO, Quarty BT. Thirty-month follow up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98:359\u2013370.", "ArticleIdList": ["15228717"]}, {"Citation": "Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8:e2953. doi: 10.1371/journal.pntd.0002953.", "ArticleIdList": ["10.1371/journal.pntd.0002953", "PMC4072596", "24968000"]}, {"Citation": "Aziz MA, Diallo S, Diop IM, Lariviere M, Porta M. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet. 1982;2(8291):171\u2013173. doi: 10.1016/s0140-6736(82)91026-1.", "ArticleIdList": ["10.1016/s0140-6736(82)91026-1", "6123884"]}, {"Citation": "Bach T, Galbiati S, Kennedy JK, Deye G, Nomicos EYH, Codd EE, Garcia HH, Horton J, Gilman RH, Gonzalez AE, Winokur P, An G. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy adults in an open-label phase 1 multiple ascending dose and food effect study. Antimicrob Agents Chemother. 2020;64(11):e01018\u2013e1020. doi: 10.1128/AAC.01018-20.", "ArticleIdList": ["10.1128/AAC.01018-20", "PMC7577123", "32816721"]}, {"Citation": "Bah GS, Schneckener S, Hahnel SR, Bayang NH, Fieseler H, Schmuck GM, Krebber R, Sarr A, Terjung C, Ngangyung HF, Ekale DD, Mfopit YM, Rufener L, Graham-Brown J, Tanya V, Glenschek-Sieberth M, Kulke D, Makepeace BL. Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis. PLoS Pathog. 2021;17(6):e1009601. doi: 10.1371/journal.ppat.1009601.", "ArticleIdList": ["10.1371/journal.ppat.1009601", "PMC8202924", "34077488"]}, {"Citation": "Banla M, Tchalim S, Karabou PK, Gantin RG, Agba AI, K\u00e9re-Banla A, Helling-Giese G, Heuschkel C, Schulz-Key H, Soboslay PT. Sustainable control of onchocerciasis: ocular pathology in onchocerciasis patients treated annually with ivermectin for 23 years: a cohort study. PLoS ONE. 2014;9(6):e98411. doi: 10.1371/journal.pone.0098411.", "ArticleIdList": ["10.1371/journal.pone.0098411", "PMC4041847", "24887413"]}, {"Citation": "Basset D, Bouree P, Basset A, Lariviere M. Effets de la di\u00e9thylcarbamazine et de l\u2019ivermectine sur la mobilisation des microfilaires d\u2019Onchocerca volvulus [Effects of diethylcarbamazine and ivermectin on the mobilization of microfilariae of Onchocerca volvulus] Pathol Biol (Paris) 1989;37(5 Pt 2):668\u201372.", "ArticleIdList": ["2797892"]}, {"Citation": "Belogurov GA, Vassylyeva MN, Sevostyanova A, Appleman JR, Xiang AX, Lira R, Webber SE, Klyuyev S, Nudler E, Artsimovitch I, Vassylyev DG. Transcription inactivation through local refolding of the RNA polymerase structure. Nature. 2009;457(7227):332\u2013335. doi: 10.1038/nature07510.", "ArticleIdList": ["10.1038/nature07510", "PMC2628454", "18946472"]}, {"Citation": "Bianco AE, Nwachukwu MA, Townson S, Doenhoff MJ, Muller RL. Evaluation of drugs against onchocerca microfilariae in an inbred mouse model. Trop Med Parasitol. 1986;37:39\u201345.", "ArticleIdList": ["3486446"]}, {"Citation": "Bosshardt SC, McCall JW, Coleman SU, Jones KL, Petit TA, Klei TR. Prophylactic activity of tetracyclineagainst Brugia pahangiinfection in jirds (Meriones unguiculatus) J Parasitol. 1993;79:775\u2013777.", "ArticleIdList": ["8410553"]}, {"Citation": "Boussinesq M, Chippaux JP. A controlled prospective trial of the prophylactic effect of a single dose of ivermectin against Onchocerca volvulus. Parasite. 2001;8(3):255\u2013259. doi: 10.1051/parasite/2001083255.", "ArticleIdList": ["10.1051/parasite/2001083255", "11584757"]}, {"Citation": "Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemio logy and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J. 2003;2(Suppl 1):S4. doi: 10.1186/1475-2883-2-S1-S4.", "ArticleIdList": ["10.1186/1475-2883-2-S1-S4", "PMC2147657", "14975061"]}, {"Citation": "Boussinesq M, Fobi G, Kuesel AC. Alternative treatment strategies to accelerate the elimination of onchocerciasis. Int Health. 2018;10:i40\u2013i48. doi: 10.1093/inthealth/ihx054.", "ArticleIdList": ["10.1093/inthealth/ihx054", "PMC5881258", "29471342"]}, {"Citation": "Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, Okello DO, Ososanya OO, Ovuga EB, Noma M, Kale OO, Burnham GM, Remme JH. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health. 1998;3(12):951\u2013961. doi: 10.1046/j.1365-3156.1998.00339.x.", "ArticleIdList": ["10.1046/j.1365-3156.1998.00339.x", "9892280"]}, {"Citation": "Budden FH. The natural history of ocular onchocerciasis over a period of 14\u201315 years and the effect on this of a single course of suramin therapy. Trans R Soc Trop Med Hyg. 1976;70(5\u20136):484\u2013491. doi: 10.1016/0035-9203(76)90134-6.", "ArticleIdList": ["10.1016/0035-9203(76)90134-6", "841651"]}, {"Citation": "Bulman CA, Bidlow CM, Lustigman S, Cho- Ngwa F, Williams D, Rasc\u00f3n AA, Jr, Tricoche N, Samje M, Bell A, Suzuki B, Lim KC, Supakorndej N, Supakorndej P, Wolfe AR, Knudsen GM, Chen S, Wilson C, Ang KH, Arkin M, Gut J, Franklin C, Marcellino C, McKerrow JH, Debnath A, Sakanari JA. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis. PLoS Negl Trop Dis. 2015;9(2):e0003534. doi: 10.1371/journal.pntd.0003534.", "ArticleIdList": ["10.1371/journal.pntd.0003534", "PMC4336141", "25700363"]}, {"Citation": "Burnham GM. Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi. Trans R Soc Trop Med Hyg. 1993;87(3):313\u20137. doi: 10.1016/0035-9203(93)90144-f.", "ArticleIdList": ["10.1016/0035-9203(93)90144-f", "8236405"]}, {"Citation": "Burnham G. Ivermectin treatment of onchocercal skin lesions: observations from a placebo-controlled, double-blind trial in Malawi. Am J Trop Med Hyg. 1995;52(3):270\u2013276. doi: 10.4269/ajtmh.52-270.", "ArticleIdList": ["10.4269/ajtmh.52-270", "PMC4750961", "7694970"]}, {"Citation": "Burnham G. Onchocerciasis. Lancet. 1998;351:1341\u20131346.", "ArticleIdList": ["9643811"]}, {"Citation": "Campbell WC. Progress and prospects in the chemotherapy of nematode infections of man and other animals. J Nematol. 1983;15:608\u2013615.", "ArticleIdList": ["PMC2618324", "19295856"]}, {"Citation": "Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901\u2013912. doi: 10.1016/s0092-8674(01)00286-0.", "ArticleIdList": ["10.1016/s0092-8674(01)00286-0", "11290327"]}, {"Citation": "Capparelli EV, Bricker-Ford R, Rogers MJ, McKerrow JH, Reed SL. Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrob Agents Chemother. 2016;61(1):e01947\u2013e2016. doi: 10.1128/AAC.01947-16.", "ArticleIdList": ["10.1128/AAC.01947-16", "PMC5192119", "27821451"]}, {"Citation": "Chavasse DC, Davies JB. In vitro effects of ivermectin on Onchocerca volvulus microfilariae assessed by observation and by inoculation into Similium damnosum sensu lato. Trans R Soc Trop Med Hyg. 1990;84:707\u2013708.", "ArticleIdList": ["2278078"]}, {"Citation": "Chavasse DC, Post RJ, Lemoh PA, Whitworth JA. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop Med Parasitol. 1992;43(4):256\u2013262.", "ArticleIdList": ["1293732"]}, {"Citation": "Chen W, Terada M, Cheng JT. Characterization of subtypes of gammaaminobutyric acid receptors in an Ascaris muscle preparation by binding assay and binding of PF1022A, a new anthelmintic, on the receptors. Parasitol Res. 1996;82:97\u2013101.", "ArticleIdList": ["8825201"]}, {"Citation": "Chesnais CB, Pion SD, Boulle C, Gardon J, et al. Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa. EClinMed. 2020;28:100582.", "ArticleIdList": ["PMC7700892", "33294807"]}, {"Citation": "Chippaux JP, Boussinesq M, Fobi G, Lafleur C, Audug\u00e9 A, Banos MT, Ngosso A, Prod\u2019hon J. Effect of repeated ivermectin treatments on ocular onchocerciasis: evaluation after six to eight doses. Ophthalmic Epidemiol. 1999;6(4):229\u2013246. doi: 10.1076/opep.6.4.229.4185.", "ArticleIdList": ["10.1076/opep.6.4.229.4185", "10544338"]}, {"Citation": "Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232\u2013260.", "ArticleIdList": ["PMC99026", "11381101"]}, {"Citation": "Cho-Ngwa F, Mbah GE, Ayiseh RB, Ndi EM, Monya E, Tumanjong IM, et al. Development and validation of an Onchocerca ochengi adult male worm gerbil model for macrofilaricidal drug screening. PLoS Negl Trop Dis. 2019;13(7):e0007556. doi: 10.1371/journal.pntd.0007556.", "ArticleIdList": ["10.1371/journal.pntd.0007556", "PMC6625737", "31260456"]}, {"Citation": "Churchill DR, Godfrey-Faussett P, Birley HD, Malin A, Davidson RN, Bryceson AD. A trial of a three-dose regimen of ivermectin for the treatment of patients with onchocerciasis in the UK. Trans R Soc Trop Med Hyg. 1994;88(2):242. doi: 10.1016/0035-9203(94)90315-8.", "ArticleIdList": ["10.1016/0035-9203(94)90315-8", "8036688"]}, {"Citation": "Clare RH, Cook DA, Johnston KL, Ford L, Ward SA, Taylor MJ. Development and validation of a high-throughput anti-Wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis. J Biomol Screen. 2015;20(1):64\u201369. doi: 10.1177/1087057114551518.", "ArticleIdList": ["10.1177/1087057114551518", "25278497"]}, {"Citation": "Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, deVlas SJ. Elimination of African onchocerciasis: modelling the impact of increasing the frequency of ivermectin mass treatment. PLoS ONE. 2014;9:e115886. doi: 10.1371/journal.pone.0115886.", "ArticleIdList": ["10.1371/journal.pone.0115886", "PMC4278850", "25545677"]}, {"Citation": "Cousens SN, Cassels-Brown A, Murdoch I, Babalola OE, Jatau D, Alexander ND, Evans JE, Danboyi P, Abiose A, Jones BR. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bull World Health Organ. 1997;75(3):229\u201336.", "ArticleIdList": ["PMC2486957", "9277010"]}, {"Citation": "Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, Brown KR, Rock D, Chen CY, Schwertschlag US. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol. 2003;43(10):1108\u20131115. doi: 10.1177/0091270003257456.", "ArticleIdList": ["10.1177/0091270003257456", "14517193"]}, {"Citation": "Crompton DWT, World Health Organization . Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006."}, {"Citation": "Dadzie KY, Bird AC, Awadzi K, et al. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br J Ophthalmol. 1987;71(2):78\u201385. doi: 10.1136/bjo.71.2.78.", "ArticleIdList": ["10.1136/bjo.71.2.78", "PMC1041095", "3548811"]}, {"Citation": "Dadzie KY, Awadzi K, Bird AC, Schulz-Key H. Ophthalmological results from a placebo controlled comparative 3-dose ivermectin study in the treatment of onchocerciasis. Trop Med Parasitol. 1989;40(3):355\u2013360.", "ArticleIdList": ["2694314"]}, {"Citation": "De Sole G, Dadzie KY, Giese J, Remme J. Lack of adverse reactions in ivermectin treatment of onchocerciasis. Lancet. 1990;335(8697):1106\u20131107. doi: 10.1016/0140-6736(90)92687-d.", "ArticleIdList": ["10.1016/0140-6736(90)92687-d", "1970412"]}, {"Citation": "Debrah AY, Specht S, Klarmann-Schulz U, Batsa L, Mand S, Marfo- Debrekyei Y, Fimmers R, Dubben B, Kwarteng A, Osei- Atweneboana M, Boakye D, Ricchiuto A, B\u00fcttner M, Adjei O, Mackenzie CD, Hoerauf A. Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo-controlled, double-blind trial. Clin Infect Dis. 2015;61(4):517\u2013526. doi: 10.1093/cid/civ363.", "ArticleIdList": ["10.1093/cid/civ363", "PMC4518165", "25948064"]}, {"Citation": "Debrah BL, Klarmann-Schulz U, Osei-Mensah J, Dubben B, Fischer K, Mubarik Y, Ayisi-Boateng NK, Ricchiuto A, Fimmers R, Konadu P, Nadal J, Gruetzmacher B, Weil G, Kazura JW, King CL, Debrah AY, Hoerauf A. Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial. Clin Infect Dis. 2020;71(4):933\u2013943. doi: 10.1093/cid/ciz889.", "ArticleIdList": ["10.1093/cid/ciz889", "PMC7428389", "31536624"]}, {"Citation": "Devaney E, Howells RE. The microfilaricidal activity of ivermectin in vitro and in vivo. Tropenrnedizin Und Parasitologie. 1984;35:47\u201349.", "ArticleIdList": ["6546818"]}, {"Citation": "Diallo S, Larivi\u00e8re M, Diop Mar I, N\u2019Dir O, N\u2019Diaye R, Badiane S, Porta M, Aziz M. Conduite au S\u00e9n\u00e9gal des premi\u00e8res \u00e9tudes d\u2019efficacit\u00e9 et de tol\u00e9rance de l\u2019ivermectine (MK 933) dans l\u2019onchocercose humaine [Management in Senegal of the 1st efficacy and tolerability studies of ivermectin (MK 933) in human onchocerciasis] Bull Soc Pathol Exot Filiales. 1984;77(2):196\u2013205.", "ArticleIdList": ["6373039"]}, {"Citation": "Diallo S, Aziz MA, Lariviere M, Diallo JS, Diop-Mar I, N\u2019Dir O, Badiane S, PY D, Schulz-Key H, Gazotte P, Victorius A, A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo-controlled study of Senegalese patients with onchocerciasis. Trans Roy Soc Trop Med Hyg. 1986;80(6):927\u2013934. doi: 10.1016/0035-9203(86)90262-2.", "ArticleIdList": ["10.1016/0035-9203(86)90262-2", "3299905"]}, {"Citation": "Dominguez-Vazquez A, Taylor HR, Greene BM, Ruvalcaba-Macias AM, Rivas-Alcala AR, Murphy RP, Beltran-Hernandez F. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet. 1983;1(8317):139\u2013143. doi: 10.1016/s0140-6736(83)92753-8.", "ArticleIdList": ["10.1016/s0140-6736(83)92753-8", "6130195"]}, {"Citation": "Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, Chippaux JP. Effets secondaires du traitement de la loase hypermicrofilar\u00e9mique par l\u2019ivermectine [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin] Bull Soc Pathol Exot. 1995;88(3):105\u201312.", "ArticleIdList": ["8555762"]}, {"Citation": "Duke BO. The effects of drugs on Onchocerca volvulus trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol. Bull World Health Organ. 1968;39(2):157\u201367.", "ArticleIdList": ["PMC2554546", "4881068"]}, {"Citation": "Duke BO, Zea-Flores G, Castro J, Cupp EW, Mu\u00f1oz B. Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1990;43(6):657\u2013664. doi: 10.4269/ajtmh.1990.43.657.", "ArticleIdList": ["10.4269/ajtmh.1990.43.657", "2267970"]}, {"Citation": "Duke BO, Pacqu\u00e9 MC, Mu\u00f1oz B, Greene BM, Taylor HR. Viability of adult Onchocerca volvulus after six 2-weekly doses of ivermectin. Bull World Health Organ. 1991;69(2):163\u20138.", "ArticleIdList": ["PMC2393085", "1860146"]}, {"Citation": "Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B. Comparison of the effects of a single dose and of four six-monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1991;45(1):132\u2013137. doi: 10.4269/ajtmh.1991.45.132.", "ArticleIdList": ["10.4269/ajtmh.1991.45.132", "1867345"]}, {"Citation": "Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B. Effects of three-month doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1992;46(2):189\u2013194. doi: 10.4269/ajtmh.1992.46.189.", "ArticleIdList": ["10.4269/ajtmh.1992.46.189", "1539754"]}, {"Citation": "Duke BO. Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms. Parasitology. 2005;130(Pt 4):447\u2013453. doi: 10.1017/s0031182004006766.", "ArticleIdList": ["10.1017/s0031182004006766", "15830819"]}, {"Citation": "Fendt J, Hamm DM, Banla M, Schulz-Key H, Wolf H, Helling-Giese G, Heuschkel C, Soboslay PT. Chemokines in onchocerciasis patients after a single dose of ivermectin. Clin Exp Immunol. 2005;142(2):318\u2013326. doi: 10.1111/j.1365-2249.2005.02910.x.", "ArticleIdList": ["10.1111/j.1365-2249.2005.02910.x", "PMC1809504", "16232219"]}, {"Citation": "Fobi G, Gardon J, Kamgno J, Aimard-Favennec L, Lafleur C, Gardon-Wendel N, Brian O, Boussinesq M. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against O. volvulus: ophthalmological results. Trans Roy Soc Trop Med Hyg. 2005;99:279\u2013288.", "ArticleIdList": ["15708387"]}, {"Citation": "Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, Piotrowski H, Dean L, Njouendou AJ, Ekanya R, Ndongmo WPC, Fung EG, Nnamdi DB, Abong RA, Beng AA, Eyong ME, Ndzeshang BL, Nkimbeng DA, Teghen S, Suireng A, Ashu EE, Kah E, Murdoch MM, Thomson R, Theobald S, Enyong P, Turner JD, Taylor MJ. Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. BMJ Glob Health. 2021;6(1):e003248. doi: 10.1136/bmjgh-2020-003248.", "ArticleIdList": ["10.1136/bmjgh-2020-003248", "PMC7802695", "33431378"]}, {"Citation": "Fischer C, Ibiricu Urriza I, Bulman CA, Lim K, Gut J, Lachau-Durand S, Engelen M, Quirynen L, Tekle F, Baeten B, Beerntsen B, Lustigman S, Sakanari J. Efficacy of subcutaneous doses and a new oral amorphous solid dispersion formulation of flubendazole on male jirds (Meriones unguiculatus) infected with the filarial nematode Brugia pahangi. PLoS Negl Trop Dis. 2019;13(1):e0006787. doi: 10.1371/journal.pntd.0006787.", "ArticleIdList": ["10.1371/journal.pntd.0006787", "PMC6334909", "30650084"]}, {"Citation": "Gandjui NVT, Njouendou AJ, Gemeg EN, Fombad FF, Ritter M, Kien CA, et al. Establishment of an in vitro culture system to study the developmental biology of Onchocerca volvulus with implications for anti-Onchocerca drug discovery and screening. PLoS Negl Trop Dis. 2021;15(2):e0008513. doi: 10.1371/journal.pntd.0008513.", "ArticleIdList": ["10.1371/journal.pntd.0008513", "PMC7899360", "33561123"]}, {"Citation": "Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue DBO. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360(9328):203\u2013210. doi: 10.1016/S0140-6736(02)09456-4.", "ArticleIdList": ["10.1016/S0140-6736(02)09456-4", "12133654"]}, {"Citation": "Gillon J-Y, Dennison J, van den Berg F, Delhomme S, Dequatre Cheeseman K, Pe\u00f1a Rossi C, Strub Wourgaft N, Specht S, Pedrique B, Monnot F, Skrabs S, Rodriguez M-L, Stass H (2021) Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects. Brit Jnl Clinical Pharma 1\u201312. 10.1111/bcp.14816", "ArticleIdList": ["PMC8518114", "33759250"]}, {"Citation": "Global Burden of Disease (2018). Keys Facts. [(Accessed on 24 May 2021)] Available online: https://www.who.int/news-room/fact-sheets/detail/onchocerciasis."}, {"Citation": "Greene BM, Taylor HR, Cupp EW, Murphy RP, White AT, Aziz MA, Schulz-Key H, D\u2019Anna SA, Newland HS, Goldschmidt LP, Auer C, Handsen AP, Freeman SV, Reber EW, Williams MP. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med. 1985;313(3):133\u2013138. doi: 10.1056/NEJM198507183130301.", "ArticleIdList": ["10.1056/NEJM198507183130301", "3892293"]}, {"Citation": "Greene BM, Dukuly ZD, Mu\u00f1oz B, White AT, Pacqu\u00e9 M, Taylor HR. A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis. 1991;163(2):376\u2013380. doi: 10.1093/infdis/163.2.376.", "ArticleIdList": ["10.1093/infdis/163.2.376", "1988521"]}, {"Citation": "Grobusch MP, Kombila M, Autenrieth I, et al. No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans. Parasitol Res. 2003;90:405\u2013408. doi: 10.1007/s00436-003-0872-z.", "ArticleIdList": ["10.1007/s00436-003-0872-z", "12748849"]}, {"Citation": "Harder A, Holden-Dye L, Walker R, Wunderlich F. Mechanisms of action of emodep side. Parasitol Res. 2005;97(Suppl 1):1\u201310.", "ArticleIdList": ["16228263"]}, {"Citation": "Hermans PG, Hart CA, Trees AJ (2001) In vitro activity of antimicrobial agents against the endosymbiont Wolbachia pipientis. J Antimicrob Chemother 47(5):659\u2013663. 10.1093/jac/47.5.659", "ArticleIdList": ["11328780"]}, {"Citation": "Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fleischer B, B\u00fcttner DW. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. 2000;355(9211):1242\u20131243. doi: 10.1016/S0140-6736(00)02095-X.", "ArticleIdList": ["10.1016/S0140-6736(00)02095-X", "10770311"]}, {"Citation": "Hoerauf A, Mand S, Adjei O, Fleischer B, B\u00fcttner DW. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. The Lancet. 2001;357(9266):1415\u20131416. doi: 10.1016/s0140-6736(00)04581-5.", "ArticleIdList": ["10.1016/s0140-6736(00)04581-5", "11356444"]}, {"Citation": "Hoerauf A, Mand S, Volkmann L, B\u00fcttner M, Marfo-Debrekyei Y, Taylor M, Adjei O, B\u00fcttner DW. Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect. 2003;5(4):261\u2013273. doi: 10.1016/s1286-4579(03)00026-1.", "ArticleIdList": ["10.1016/s1286-4579(03)00026-1", "12706439"]}, {"Citation": "Hoerauf A, Specht S, B\u00fcttner M, Pfarr K, Mand S, Fimmers R, Marfo-Debrekyei Y, Konadu P, Debrah AY, Bandi C, Brattig N, Albers A, Larbi J, Batsa L, Taylor MJ, Adjei O, B\u00fcttner DW. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol. 2008;197(3):295\u2013311. doi: 10.1007/s00430-007-0062-1.", "ArticleIdList": ["10.1007/s00430-007-0062-1", "PMC2668626", "17999080"]}, {"Citation": "Hong WD, Benayoud F, Nixon GL, Ford L, Johnston KL, Clare RH, Cassidy A, Dan C, Siu A, Shiotani M, Webborn PJH, Kavanagh S, Aljayyoussi G, Murphy E, Steven A, Archer J, Struever D, Frohberger SJ, Ehrens A, H\u00fcbner MP, Hoerauf A, Roberts AP, ATM H, Tate EW, Serwa RA, Leung SC, Qie L, Berry NG, Gusovsky F, Hemingway J, Turner JD, Taylor MJ, Ward SA, O\u2019Neill PM. AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis. Proc Natl Acad Sci U S A. 2019;116(4):1414\u20131419. doi: 10.1073/pnas.", "ArticleIdList": ["10.1073/pnas", "PMC6347715", "30617067"]}, {"Citation": "H\u00fcbner MP, Koschel M, Struever D, Nikolov V, Frohberger SJ, Ehrens A, et al. In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae. PLoS Negl Trop Dis. 2019;13(8):e0007636. doi: 10.1371/journal.pntd.0007636.", "ArticleIdList": ["10.1371/journal.pntd.0007636", "PMC6695197", "31381563"]}, {"Citation": "H\u00fcbner MP, Ehrens A, Koschel M, Dubben B, Lenz F, Frohberger SJ, Specht S, Quirynen L, Lachau-Durand S, Tekle F, Baeten B, Engelen M, Mackenzie CD, Hoerauf A. Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds. PLoS Negl Trop Dis. 2019;13(1):e0006320. doi: 10.1371/journal.pntd.0006320.", "ArticleIdList": ["10.1371/journal.pntd.0006320", "PMC6334906", "30650105"]}, {"Citation": "H\u00fcbner MP, Martin C, Specht S, Koschel M, Dubben B, Frohberger SJ, Ehrens A, Fendler M, Struever D, Mitre E, Vallarino-Lhermitte N, Gokool S, Lustigman S, Schneider M, Townson S, Hoerauf A, Scandale I. Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec motility in vitro. PLoS Negl Trop Dis. 2020;14(7):e0008427. doi: 10.1371/journal.pntd.0008427.", "ArticleIdList": ["10.1371/journal.pntd.0008427", "PMC7365463", "32628671"]}, {"Citation": "Irschik H, Jansen R, Hofle G, Gerth K, Reichenbach H. The corallo-pyronins, new inhibitors of bacterial RNA synthesis fromMyxobacte-ria. J Antibiot (tokyo) 1985;38:145\u2013152.", "ArticleIdList": ["2581926"]}, {"Citation": "Janko C, Geyer J. Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin. J Vet Pharmacol Ther. 2013;36(3):275\u2013284.", "ArticleIdList": ["22834856"]}, {"Citation": "Jawahar S, Tricoche N, Bulman CA, Sakanari J, Lustigman S. Drugs that target early stages of Onchocerca volvulus: a revisited means to facilitate the elimination goals for onchocerciasis. PLoS Negl Trop Dis. 2021;15(2):e0009064. doi: 10.1371/journal.pntd.0009064.", "ArticleIdList": ["10.1371/journal.pntd.0009064", "PMC7891776", "33600426"]}, {"Citation": "Jittamala P, Monteiro W, Smit MR, Pedrique B, Specht S, Chaccour CJ, Dard C, Del Giudice P, Khieu V, Maruani A, Failoc-Rojas VE, S\u00e1ez-de-Ocariz M, Soriano-Arandes A, Piquero-Casals J, Faisant A, Brenier-Pinchart MP, Wimmersberger D, Coulibaly JT, Keiser J, Boralevi F, Sokana O, Marks M, Engelman D, Romani L, Steer AC, von Seidlein L, White NJ, Harriss E, Stepniewska K, Humphreys GS, Kennon K, Guerin PJ, Kobylinski KC. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: is it time to reconsider the current contraindication? PLoS Negl Trop Dis. 2021;15(3):e0009144. doi: 10.1371/journal.pntd.0009144.", "ArticleIdList": ["10.1371/journal.pntd.0009144", "PMC7968658", "33730099"]}, {"Citation": "Johnston KL, Ford L, Umareddy I, Townson S, Specht S, Pfarr K, Hoerauf A, Altmeyer R, Taylor MJ. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. Int. J. Parasitol: Drugs Drug Resist. 2014;4(3):278\u201386.", "ArticleIdList": ["PMC4266796", "25516838"]}, {"Citation": "Kamgno J, Gardon J, Gardon-Wendel N, Demanga-Ngangue DBO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004;98(8):496\u2013504. doi: 10.1016/j.trstmh.2003.10.018.", "ArticleIdList": ["10.1016/j.trstmh.2003.10.018", "15186939"]}, {"Citation": "Kamgno J, Pion SD, Chesnais CB, Bakalar MH, D\u2019Ambrosio MV, Mackenzie CD, Nana-Djeunga HC, Gounoue-Kamkumo R, Njitchouang GR, Nwane P, Tchatchueng-Mbouga JB, Wanji S, Stolk WA, Fletcher DA, Klion AD, Nutman TB, Boussinesq M. A Test-and-Not-Treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med. 2017;377(21):2044\u20132052. doi: 10.1056/NEJMoa1705026.", "ArticleIdList": ["10.1056/NEJMoa1705026", "PMC5629452", "29116890"]}, {"Citation": "Katabarwa MN, Eyamba A, Nwane P, Enyong P, Kamgno J, et al. Fifteen years of annual masstreatment of onchocerciasis with ivermectin have not interrupted transmission in the west region ofcameroon. J Parasitol Res. 2013;2013:420928. doi: 10.1155/2013/420928.", "ArticleIdList": ["10.1155/2013/420928", "PMC3652197", "23691275"]}, {"Citation": "Kempf DJ, Marsh KC. Assembling pharma resources to tackle diseases of underserved populations. ACS Med Chem Lett. 2020;11(6):1094\u20131100.", "ArticleIdList": ["PMC7294558", "32550987"]}, {"Citation": "Kiki-Mvouaka S, M\u00e9nez C, Borin C, Lyazrhi F, Foucaud-Vignault M, Dupuy J, Collet X, Alvinerie M, Lespine A. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos. 2010;38(4):573\u2013580. doi: 10.1124/dmd.109.030700.", "ArticleIdList": ["10.1124/dmd.109.030700", "20089736"]}, {"Citation": "Klarmann-Schulz U, Specht S, Debrah AY, Batsa L, Ayisi-Boateng NK, Osei-Mensah J, Mu barik Y, Konadu P, Ricchiuto A, Fimmers R, Arriens S, Dubben B, Ford L, Taylor M, Hoerauf A. Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial. PLoS Negl Trop Dis. 2017;11(1):e0005156. doi: 10.1371/journal.pntd.0005156.", "ArticleIdList": ["10.1371/journal.pntd.0005156", "PMC5215804", "28056021"]}, {"Citation": "Korth-Bradley JM, Parks V, Chalon S, Gourley I, Matschke K, Gossart S, Bryson P, Fleckenstein L. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother. 2011;55(11):5200\u20135204. doi: 10.1128/AAC.00311-11.", "ArticleIdList": ["10.1128/AAC.00311-11", "PMC3195050", "21896908"]}, {"Citation": "Korth-Bradley JM, Parks V, Patat A, Matschke K, Mayer P, Fleckenstein L. Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Pharmacol Drug Dev. 2012;1:32\u201337.", "ArticleIdList": ["27206144"]}, {"Citation": "Kr\u00fccken J, HoldenDye L, Keiser J, Prichard R, Townson S, Makepeace BL, H\u00fcbner MP, Hehnel SR, Scandale I, Harder A, Kulke D. Development of emodepside as a possible adulticidal treatment for human onchocerciasis-the fruit of a successful industrial-academic collaboration. PloS Path. 2021;17(7):e1009682.", "ArticleIdList": ["PMC8297762", "34293063"]}, {"Citation": "Kulke D, von Samson-Himmelstjerna G, Miltsch SM, Wolstenholme AJ, Jex AR, et al. Characterization of the Ca2+ -gated and voltage-dependent K+ -channel Slo-1 of nematodes and its interaction with emodepside. PLoS Negl Trop Dis. 2014;8(12):e3401. doi: 10.1371/journal.pntd.0003401.", "ArticleIdList": ["10.1371/journal.pntd.0003401", "PMC4270693", "25521608"]}, {"Citation": "Lacey E. Mode of action of benzimidazoles. Parasitol Today. 1990;6:112\u2013115.", "ArticleIdList": ["15463312"]}, {"Citation": "Lachau-Durand S, Lammens L, van der Leede B, Van Gompel J, Bailey G, Engelen M, Lampo A. Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients. PLoS Negl Trop Dis. 2019;13(1):e0007026. doi: 10.1371/journal.pntd.0007026.", "ArticleIdList": ["10.1371/journal.pntd.0007026", "PMC6334931", "30650076"]}, {"Citation": "Lariviere M, Aziz M, Weimann D, Ginoux J, Gaxotte P, Vingtain P, Beauvais B, Deroin F, Schulz-Key H, Baset D, Sarfati C. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet. 1985;326(8448):174\u2013177. doi: 10.1016/s0140-6736(85)91496-5.", "ArticleIdList": ["10.1016/s0140-6736(85)91496-5", "2862370"]}, {"Citation": "Larivi\u00e8re M, Beauvais B, Derouin F, Basset D, Basset A, Sarfati C. L\u2019Ivermectine dans le traitement et la prophylaxie de l\u2019onchocercose humaine [Ivermectin in the treatment and prevention of human onchocerciasis] Ann Med Interne (Paris) 1987;138(1):49\u201351.", "ArticleIdList": ["3296903"]}, {"Citation": "Larivi\u00e8re M, Beauvais B, Aziz M, Garin JF, Abeloos J, Derouin F, Bamba M, Bossebceuf C, Ferlytherizol M, Sarfati C, et al. A study in the Ivory Coast (1985\u20131987) of the efficacy and tolerance of ivermectin (Mectizan) in human onchocerciasis. I. A comparative double-blind study of 220 patients with onchocerciasis treated with a single oral dose of 100, 150 or 200 mcg/kg. Bull Soc Pathol Exot Filiales. 1989;82(1):35\u201347.", "ArticleIdList": ["2545366"]}, {"Citation": "Lakwo TL, Gasarasi DB. Non-adherence to community directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania. East Afr Med J. 2006;83(6):326\u2013332. doi: 10.4314/eamj.v83i6.9440.", "ArticleIdList": ["10.4314/eamj.v83i6.9440", "16989378"]}, {"Citation": "Lenk EJ, Moungui HC, Boussinesq M, Kamgno J, Nana-Djeunga HC, Fitzpatrick C, Peultier A, Klion AD, Fletcher DA, Nutman TB, Pion SD, Niamsi-Emalio Y, Redekop WK, Severens JL, Stolk WA. A Test-and-Not-Treat strategy for onchocerciasis elimination in Loa loa-coendemic areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon. Clin Infect Dis: an Official Publication of the Infectious Diseases Society of America. 2020;70(8):1628\u20131635. doi: 10.1093/cid/ciz461.", "ArticleIdList": ["10.1093/cid/ciz461", "PMC7146010", "31165855"]}, {"Citation": "Longo M, Zanoncelli S, Messina M, Scandale I, Mackenzie C, Geary T, Marsh K, Lindley D, Mazue G. In vivo preliminary investigations of the effects of the benzimidazole anthelmintic drug flubendazole on rat embryos and fetuses. Reprod Toxicol. 2014;49:33\u201342. doi: 10.1016/j.reprotox.2014.06.009.", "ArticleIdList": ["10.1016/j.reprotox.2014.06.009", "24994687"]}, {"Citation": "Mabey D, Whitworth JA, Eckstein M, Gilbert C, Maude G, Downham M. The effects of multiple doses of ivermectin on ocular onchocerciasis. A Six-Year Follow-up Ophthalmology. 1996;103(7):1001\u20131008. doi: 10.1016/s0161-6420(96)30574-5.", "ArticleIdList": ["10.1016/s0161-6420(96)30574-5", "8684787"]}, {"Citation": "Mackenzie CD, Geary TG. Flubendazole, a potentially valuable macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Review of Anti- Infective Therapy. 2011;9:497\u2013501.", "ArticleIdList": ["21609260"]}, {"Citation": "Makenga Bof JC, Maketa V, Bakajika DK, Ntumba F, Mpunga D, Murdoch ME, Hopkins A, Noma MM, Zour\u00e9 H, Tekle AH, Katabarwa MN, Lutumba P. Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment. Trop Med Int Health. 2015;20(1):48\u201362. doi: 10.1111/tmi.12397.", "ArticleIdList": ["10.1111/tmi.12397", "25302560"]}, {"Citation": "Mandro M, Siewe Fodjo JN, Dusabimana A, Mukendi D, Haesendonckx S, Lokonda R, Nakato S, Nyisi F, Abhafule G, Wonya\u2019rossi D, Hotterbeekx A, Abrams S, Colebunders R, Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy treated with phenobarbital: a randomized clinical trial in the Democratic Republic of Congo. Pathogens. 2020;9(3):205. doi: 10.3390/pathogens9030205.", "ArticleIdList": ["10.3390/pathogens9030205", "PMC7157533", "32164367"]}, {"Citation": "Masud H, Qureshi TQ, Dukley M. Effects of ivermectin with and without doxycycline on clinical symptoms of onchocerciasis. J Coll Physicians Surg Pak. 2009;19(1):34\u201338.", "ArticleIdList": ["19149978"]}, {"Citation": "Michiels M, Hendriks R, Heykants J, van den Bossche H. The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther. 1982;256(2):180\u2013191.", "ArticleIdList": ["7103610"]}, {"Citation": "Milton P, Hamley JID, Walker M, Bas\u00e1\u00f1ez MG (2020) Moxidectin: an oral treatment for human onchocerciasis. Expert Review of Anti-Infective Therapy 1\u201315. 10.1080/14787210.2020.1792772", "ArticleIdList": ["32715787"]}, {"Citation": "Miltsch SM, Kr\u00fccken J, Demeler J, Janssen IJ, Kr\u00fcger N, Harder A, von Samson-Himmelstjerna G. Decreased emodepside sensitivity in unc-49 \u03b3-aminobutyric acid (GABA)-receptor-deficient Caenorhabditis elegans. Int J Parasitol. 2012;42(8):761\u2013770. doi: 10.1016/j.ijpara.2012.05.009.", "ArticleIdList": ["10.1016/j.ijpara.2012.05.009", "22727682"]}, {"Citation": "Morris CP, Evans H, Larsen SE, Mitre E. A comprehensive, model-based review of vaccine and repeat infection trials for filariasis. Clin Microbiol Rev. 2013;26(3):381\u2013421. doi: 10.1128/CMR.00002-13.", "ArticleIdList": ["10.1128/CMR.00002-13", "PMC3719488", "23824365"]}, {"Citation": "M\u00f6ssinger J, Schulz-Key H, Dietz K. Emergence of Onchocerca volvulus microfilariae from skin snips before and after treatment of patients with ivermectin. Trop Med Parasitol. 1988;39(4):313\u2013316.", "ArticleIdList": ["3067322"]}, {"Citation": "Mounsey KE, Bernigaud C, Chosidow O, McCarthy JS. Prospects for moxidectin as a new oral treatment for human scabies. PLoS Negl Trop Dis. 2016;10(3):e0004389. doi: 10.1371/journal.pntd.0004389.", "ArticleIdList": ["10.1371/journal.pntd.0004389", "PMC4795782", "26985995"]}, {"Citation": "Mu\u00f1oz J, Ballester MR, Antonijoan RM, Gich I, Rodr\u00edguez M, Colli E, Gold S, Krolewiecki AJ. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis. 2018;12(1):e0006020. doi: 10.1371/journal.pntd.0006020.", "ArticleIdList": ["10.1371/journal.pntd.0006020", "PMC5773004", "29346388"]}, {"Citation": "Murdoch I, Abiose A, Babalola O, Bird A, Cousens S, Evans J, Jones B. Ivermectin and onchocercal optic neuritis: short-term effects. Eye (lond) 1994;8(Pt 4):456\u2013461. doi: 10.1038/eye.1994.108.", "ArticleIdList": ["10.1038/eye.1994.108", "7821473"]}, {"Citation": "Mwetta E, Hills E. Community treatment with ivermectin for onchocerciasis in the east Usambara mountains. East Afr Med J. 1994;71(12):790\u2013791.", "ArticleIdList": ["7705249"]}, {"Citation": "Newland HS, White AT, Greene BM, D\u2019anna SA, Keyvan-Larijani E, Aziz MA, Williams PN, Taylor HR. Effect of single-dose invermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement. Brit J Ophthl. 1988;72:561\u2013569.", "ArticleIdList": ["PMC1041529", "3046657"]}, {"Citation": "NTD Modelling Consortium Onchocerciasis Group (2019) The World Health Organization 2030 goals for onchocerciasis: insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group. Gates Open Res 3:1545. 10.12688/gatesopenres.13067.1", "ArticleIdList": ["PMC6820451", "31723729"]}, {"Citation": "Nutman TB (2020) Onchocerciasis. Hunter\u2019s tropical medicine and emerging infectious diseases. (Tenth Edition). E. T. Ryan, D. R. Hill, T. Solomon, N. E. Aronson and T. P. Endy. London: Elsevier 116: 864\u2013871."}, {"Citation": "Ogbuagu KF, Eneanya CI. A multi-centre study of the effect of Mectizan treatment on onchocercal skin disease: clinical findings. Ann Trop Med Parasitol. 1988;92(Suppl 1):S139\u2013S145.", "ArticleIdList": ["9861280"]}, {"Citation": "O\u2019Neill A, Oliva B, Storey C, Hoyle A, Fishwick C, Chopra I. RNApolymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 2000;44:3163\u20136.", "ArticleIdList": ["PMC101622", "11036042"]}, {"Citation": "Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, Nigo MM, Kasonia K, Masembe SL, Mumbere M, Kataliko K, Larbelee JP, Kpawor M, Bolay KM, Bolay F, Asare S, Attah SK, Olipoh G, Vaillant M, Halleux CM, Kuesel AC. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207\u20131216. doi: 10.1016/S0140-6736(17)32844-1.", "ArticleIdList": ["10.1016/S0140-6736(17)32844-1", "PMC6172290", "29361335"]}, {"Citation": "Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectinin endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369:2021\u20132029.", "ArticleIdList": ["17574093"]}, {"Citation": "Patton JB, Bennuru S, Eberhard ML, Hess JA, Torigian A, Lustigman S, et al. Development of Onchocerca volvulus in humanized NSG mice and detection of parasite biomarkers in urine and serum. PLoS Negl Trop Dis. 2018;12(12):e0006977. doi: 10.1371/journal.pntd.0006977.", "ArticleIdList": ["10.1371/journal.pntd.0006977", "PMC6306240", "30540742"]}, {"Citation": "Pion SD, Grout L, Kamgno J, Nana-Djeunga H, Boussinesq M. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Trop. 2011;120(Suppl 1):S91\u2013S99. doi: 10.1016/j.actatropica.2010.05.004.", "ArticleIdList": ["10.1016/j.actatropica.2010.05.004", "20497765"]}, {"Citation": "Pionnier N, Sjoberg H, Furlong-Silva J, Marriott A, Halliday A, Archer J, Steven A, Taylor MJ, Turner JD. Eosinophil-mediated immune control of adult filarial nematode infection can proceed in the absence of IL-4 receptor signaling. J Immunol. 2020;205(3):731\u2013740. doi: 10.4049/jimmunol.1901244.", "ArticleIdList": ["10.4049/jimmunol.1901244", "PMC7372315", "32571840"]}, {"Citation": "Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, Bonneux L, Habbema JD. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172(1):204\u2013210. doi: 10.1093/infdis/172.1.204.", "ArticleIdList": ["10.1093/infdis/172.1.204", "7797912"]}, {"Citation": "Prichard R, Menez C, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134\u2013153.", "ArticleIdList": ["PMC3862425", "24533275"]}, {"Citation": "Prichard RK, Geary TG. Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance. Int J Parasitol Drugs Drug Resist. 2019;10:69\u201383. doi: 10.1016/j.ijpddr.2019.06.002.", "ArticleIdList": ["10.1016/j.ijpddr.2019.06.002", "PMC6593148", "31229910"]}, {"Citation": "Richards FO, Jr, Amann J, Arana B, Punkosdy G, Klein R, Blanco C, Lopez B, Mendoza C, Dom\u00ednguez A, Guarner J, Maguire JH, Eberhard M. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am J Trop Med Hyg. 2007;77(5):878\u2013882.", "ArticleIdList": ["17984346"]}, {"Citation": "Risch F, Ritter M, Hoerauf A, H\u00fcbner MP (2021) Human filariasis-contributions of the Lito mosoides sigmodontis and Acanthocheilonema viteae animal model. Parasitol Res. 10.1007/s00436-020-07026-2", "ArticleIdList": ["PMC8599372", "33547508"]}, {"Citation": "Saeger B, Schmitt-Wrede HP, Dehnhardt M, Benten WP, Krucken J, et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J. 2001;15:1332\u20131334.", "ArticleIdList": ["11344131"]}, {"Citation": "Sauerbrey M, Lindsay JR, Richards FO., Jr Progress toward elimination of onchocerciasis in the Americas. Int Health. 2018;10:i71\u2013i78. doi: 10.1093/inthealth/ihx039.", "ArticleIdList": ["10.1093/inthealth/ihx039", "29471334"]}, {"Citation": "Saunders M, Taubert A, Dafa'alla T, Zahner H (2008) Effect of chemotherapeutic treatment on cytokine (IFNgamma, IL-2, IL-4, IL-5, IL-10) gene transcription in response to specific antigens in Brugia malayi-infected Mastomys coucha. Parasitol Res 103(5):1163\u20131176. 10.1007/s00436-008-1112-3", "ArticleIdList": ["18679719"]}, {"Citation": "Schiefer A, Schmitz A, Sch\u00e4berle TF, Specht S, L\u00e4mmer C, Johnston KL, Vassylyev DG, K\u00f6nig GM, Hoerauf A, Pfarr K. Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo. J Infect Dis. 2012;206(2):249\u2013257. doi: 10.1093/infdis/jis341.", "ArticleIdList": ["10.1093/infdis/jis341", "PMC3490692", "22586066"]}, {"Citation": "Schiefer A, H\u00fcbner MP, Krome A, L\u00e4mmer C, Ehrens A, Aden T et al (2020) Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections. PLoS Negl Trop Dis 14(12):e0008930.10.1371/journal.pntd.0008930", "ArticleIdList": ["PMC7746275", "33284808"]}, {"Citation": "Selzer PM and Epe C (2020) Antiparasitics in animal health: Quo Vadis?Trends in Parasitology. 10.1016/j.pt.2020.09.004", "ArticleIdList": ["33039282"]}, {"Citation": "Senyonjo L, Oye J, Bakajika D, Biholong B, Tekle A, Boakye D, et al. Factors associated with ivermectin non-compliance and its potential role in sustaining Onchocerca volvulus transmission in the West Region of Cameroon. PLoSNegl Trop Dis. 2016;10(8):e0004905. doi: 10.1371/journal.pntd.0004905.", "ArticleIdList": ["10.1371/journal.pntd.0004905", "PMC4986942", "27529622"]}, {"Citation": "Shu EN, Okonkwo PO, Ogbodo SO. An improved dosing schedule for ivermectin as a microfilaricidal agent against onchocerciasis. Acta Trop. 1997;68(3):269\u2013275. doi: 10.1016/s0001-706x(97)00101-0.", "ArticleIdList": ["10.1016/s0001-706x(97)00101-0", "9492911"]}, {"Citation": "Sjoberg HT, Pionnier N, Aljayyoussi G, Metuge HM, Njouendou AJ, Chunda VC, et al. Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models. PLoS Negl Trop Dis. 2019;13(1):e0006356. doi: 10.1371/journal.pntd.0006356.", "ArticleIdList": ["10.1371/journal.pntd.0006356", "PMC6334903", "30650071"]}, {"Citation": "Soboslay PT, Newland HS, White AT, Erttmann KD, Albiez EJ, Taylor HR, Williams PN, Greene BM. Ivermectin effect on microfilariae of Onchocerca volvulus after a single oral dose in humans. Trop Med Parasitol. 1987;38(1):8\u201310.", "ArticleIdList": ["3602843"]}, {"Citation": "Somo RM, Ngosso A, Dinga JS, Enyong PA, Fobi G. A community-based trial of ivermectin for onchocerciasis control in the forest of southwestern Cameroon: clinical and parasitologic findings after three treatments. Am J Trop Med Hyg. 1993;48(1):9\u201313. doi: 10.4269/ajtmh.1993.48.9.", "ArticleIdList": ["10.4269/ajtmh.1993.48.9", "8427394"]}, {"Citation": "Soula G, Keita M, Sacko D, Sangare M, Bissan Y, Dembele D, Doumbo O, Kodio B, Pichard E, Ranque P. Tol\u00e9rance d\u2019un traitement de collectivit\u00e9s rurales atteintes d\u2019onchocercose de savane par l\u2019ivermectine au Mali [Tolerance of ivermectin treatment of rural communities infected by savannah onchocerciasis in Mali] Bull Soc Pathol Exot. 1992;85(1):47\u201352.", "ArticleIdList": ["1596958"]}, {"Citation": "Specht S, Mand S, Marfo-Debrekyei Y, Debrah A, Konadu P, Adjei O, B\u00fcttner D, Hoerauf A. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res. 2008;103(6):1303\u20131309.", "ArticleIdList": ["18679718"]}, {"Citation": "Specht S, Pfarr KM, Arriens S, H\u00fcbner MP, Klarmann-Schulz U, Koschel M, Sternberg S, Martin C, Ford L, Taylor MJ, Hoerauf A. Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model. PLoS Negl Trop Dis. 2018;12(1):e0006116. doi: 10.1371/journal.pntd.0006116.", "ArticleIdList": ["10.1371/journal.pntd.0006116", "PMC5771630", "29300732"]}, {"Citation": "Steel C, Lujan-Trangay A, Gonzalez-Peralta C, Zea-Flores G, Nutman TB. Transient changes in cytokine profiles following ivermectin treatment of onchocerciasis. J Infect Dis. 1994;170(4):962\u2013970. doi: 10.1093/infdis/170.4.962.", "ArticleIdList": ["10.1093/infdis/170.4.962", "7930742"]}, {"Citation": "Stolk WA, Walker M, Coffeng LR, Bas\u00e1\u02dcnez MG, de Vlas SJ, Required duration of mass ivermectin treatment for onchocerciasis elimimnation in Africa: a comparative modelling analysis. Parasit Vectors. 2015;8:552. doi: 10.1186/s13071-015-1159-9.", "ArticleIdList": ["10.1186/s13071-015-1159-9", "PMC4618738", "26489937"]}, {"Citation": "Tagboto SK, Townson S. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo. Ann Trop Med Parasitol. 1996;90(5):497\u2013505. doi: 10.1080/00034983.1996.11813075.", "ArticleIdList": ["10.1080/00034983.1996.11813075", "8915126"]}, {"Citation": "Tamarozzi F, Tendongfor N, Enyong PA, Esum M, Faragher B, Wanji S, Taylor MJ. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasit Vectors. 2012;5:53. doi: 10.1186/1756-3305-5-53.", "ArticleIdList": ["10.1186/1756-3305-5-53", "PMC3350421", "22433114"]}, {"Citation": "Taylor MJ, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today. 1999;15(11):437\u2013442. doi: 10.1016/s0169-4758(99)01533-1.", "ArticleIdList": ["10.1016/s0169-4758(99)01533-1", "10511685"]}, {"Citation": "Taylor HR, Murphy RP, Newland HS, White AT, D\u2019Anna SA, Keyvan-Larijani E, Aziz MA, Cupp EW, Greene BM. Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Arch Ophthalmol. 1986;104(6):863\u201370. doi: 10.1001/archopht.1986.01050180097039.", "ArticleIdList": ["10.1001/archopht.1986.01050180097039", "3521559"]}, {"Citation": "Taylor HR, Semba RD, Newland HS, Keyvan-Larijani E, White A, Dukuly Z, Greene BM. Ivermectin treatment of patients with severe ocular onchocerciasis. Am J Trop Med Hyg. 1989;40(5):494\u2013500. doi: 10.4269/ajtmh.1989.40.494.", "ArticleIdList": ["10.4269/ajtmh.1989.40.494", "2658637"]}, {"Citation": "Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol. 2005;60:245\u2013284.", "ArticleIdList": ["16230105"]}, {"Citation": "Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376:1175\u20131185.", "ArticleIdList": ["20739055"]}, {"Citation": "Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitol. 2014;141(1):119\u2013127. doi: 10.1017/S0031182013001108.", "ArticleIdList": ["10.1017/S0031182013001108", "PMC3884836", "23866958"]}, {"Citation": "Taylor MJ, von Geldern TW, Ford L, H\u00fcbner MP, Marsh K, Johnston KL, Sjoberg HT, Specht S, Pionnier N, Tyrer HE, Clare RH, Cook DAN, Murphy E, Steven A, Archer J, Bloemker D, Lenz F, Koschel M, Ehrens A, Metuge HM, Chunda VC, Ndongmo Chounna PW, Njouendou AJ, Fombad FF, Carr R, Morton HE, Aljayyoussi G, Hoerauf A, Wanji S, Kempf DJ, Turner JD, Ward SA. Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. Sci Transl Med. 2019;11(483):2086. doi: 10.1126/scitranslmed.aau2086.", "ArticleIdList": ["10.1126/scitranslmed.aau2086", "30867321"]}, {"Citation": "Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J, McKerrow JH, Reed SL, Eckmann L. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother. 2013;57(5):2029\u20132035. doi: 10.1128/AAC.01675-12.", "ArticleIdList": ["10.1128/AAC.01675-12", "PMC3632933", "23403423"]}, {"Citation": "Townson S, Connelly C, Dobinson A, Muller R. Drug activity against Onchocerca gutturosa males in vitro: a model for chemotherapeutic research on onchocerciasis. J Helminthol. 1987;61:271\u2013281.", "ArticleIdList": ["3437107"]}, {"Citation": "Townson S, Dobinson A, Connelly C, Muller R. Chemotherapy of Onchocerca lienalis microfilariae in mice: a model for the evaluation of novel compounds for the treatment of onchocerciasis. J Helminthol. 1988;62:181\u2013194.", "ArticleIdList": ["3192910"]}, {"Citation": "Townson S, Dobinson AR, Townsend J, Siemienska J, Zea-Flores G. The effects of ivermectin used in combination with other known anti-parasitic drugs on adult Onchocerca guuurosa and O. volvulus in vitro. Trans R Soc Trop Med Hyg. 1990;84:411\u2013416.", "ArticleIdList": ["2260177"]}, {"Citation": "Townson S, Tagboto SK. The effects of ivermectin on the viability of Onchocerca Iienalis microfilariae in vitro and on their subsequent development in the blackfly vector, Simulium ornatum. Trop Med Parasitol. 1991;42:31\u201337.", "ArticleIdList": ["2052853"]}, {"Citation": "Townson (2005) Activity of the cyclooctadepsipeptide emodepside against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi (conference abstract): Am J Trop Med Hyg : Official Journal of the American Society of Tropical Medicine and Hygiene 73(6, Suppl. S) 93\u201393. info:doi/"}, {"Citation": "Turner JD, Tendongfor N, Esum M, Johnston KL, Langley RS, Ford L, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis. 2010;4(4):e660. doi: 10.1371/journal.pntd.0000660.", "ArticleIdList": ["10.1371/journal.pntd.0000660", "PMC2854122", "20405054"]}, {"Citation": "Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, Prichard RK, Bas\u00e1\u02dcnez MG, Reaching the London Declaration on Neglected Tropical Diseases goals for onchocerciasis: aneconomic evaluation of increasing the frequency of ivermectin treatment inAfrica. Clin Infect Dis. 2014;59:923\u2013932. doi: 10.1093/cid/ciu467.", "ArticleIdList": ["10.1093/cid/ciu467", "PMC4166981", "24944228"]}, {"Citation": "Tweats DJ, Johnson GE, Scandale I, Whitwell J, Evans DB. Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity. Mutagenesis. 2016;31:309. doi: 10.1093/mutage/gev070.", "ArticleIdList": ["10.1093/mutage/gev070", "PMC4840262", "26443851"]}, {"Citation": "Vingtain P, Pichard E, Ginoux J, Coulibaly SM, Bissan Y, Ranque P, Thillaye B. Ivermectin and human onchocerciasis. A study of 234 onchocerciasis patients in the Republic of Mali. Bull Soc Pathol Exot Filiales. 1988;81(2):260\u201370.", "ArticleIdList": ["3046772"]}, {"Citation": "Voronin D, Tricoche N, Jawahar S, Shlossman M, Bulman CA, Fischer C, Suderman MT, Sakanari JA, Lustigman S. Development of a preliminary in vitro drug screening assay based on a newly established culturing system for pre-adult fifth-stage Onchocerca volvulus worms. PLoS Negl Trop Dis. 2019;13(1):e0007108. doi: 10.1371/journal.pntd.0007108.", "ArticleIdList": ["10.1371/journal.pntd.0007108", "PMC6353222", "30653499"]}, {"Citation": "Volkmann L, Fischer K, Taylor M, Hoerauf A. Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health. 2003;8(5):392\u2013401. doi: 10.1046/j.1365-3156.2003.01040.x.", "ArticleIdList": ["10.1046/j.1365-3156.2003.01040.x", "12753632"]}, {"Citation": "von Geldern TW, Morton HE, Clark RF, Brown BS, Johnston KL, Ford L, Specht S, Carr RA, Stolarik DF, Ma J, Rieser MJ, Struever D, Frohberger SF, Koschel M, Ehrens A, Turner JD, H\u00fcbner MP, Hoerauf A, Taylor MJ, Ward SA, Marsh K, Kempf DJ. Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. PLoS Negl Trop Dis. 2019;13(2):e0007159. doi: 10.1371/journal.pntd.0007159.", "ArticleIdList": ["10.1371/journal.pntd.0007159", "PMC6413952", "30818326"]}, {"Citation": "Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Bas\u00e1\u00f1ez MG (2015) Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin Infect Dis 60(8):1199\u20131207.\u00a010.1093/cid/ciu1152", "ArticleIdList": ["PMC4370165", "25537873"]}, {"Citation": "Walker M, Stolk WA, Dixon MA, Bottomley C, Diawara L, Traor\u00e9 MO, de Vlas SJ, Bas\u00e1\u00f1ez MG. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal. Epidemics. 2017;18:4\u201315. doi: 10.1016/j.epidem.2017.02.005.", "ArticleIdList": ["10.1016/j.epidem.2017.02.005", "PMC5340858", "28279455"]}, {"Citation": "Walker M, Pion SDS, Fang H, Gardon J, Kamgno J, Bas\u00e1\u00f1ez MG, Boussinesq M. Macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness. Clin Infect Dis. 2017;65(12):2026\u20132034. doi: 10.1093/cid/cix616.", "ArticleIdList": ["10.1093/cid/cix616", "PMC5850622", "29020189"]}, {"Citation": "Wan Sulaiman WA, Kamtchum-Tatuene J, Mohamed MH, Ramachandran V, Ching SM, Sazlly Lim SM, Hashim HZ, Inche Mat LN, Hoo FK, Basri H. Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: current perspectives. Indian J Med Res. 2019;149(6):706\u2013714. doi: 10.4103/ijmr.IJMR_454_17.", "ArticleIdList": ["10.4103/ijmr.IJMR_454_17", "PMC6755775", "31496523"]}, {"Citation": "Wanji S, Tendongfor N, Nji T, Esum M, Che JN, Nkwescheu A, Alassa F, Kamnang G, Enyong PA, Taylor MJ, Hoerauf A, Taylor DW. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit Vectors. 2009;2(1):39. doi: 10.1186/1756-3305-2-39.", "ArticleIdList": ["10.1186/1756-3305-2-39", "PMC2742514", "19712455"]}, {"Citation": "Whitworth JA, Morgan D, Maude GH, Downham MD, Taylor DW. A community trial of ivermectin for onchocerciasis in Sierra Leone: adverse reactions after the first five treatment rounds. Trans R Soc Trop Med Hyg. 1991;85(4):501\u2013505. doi: 10.1016/0035-9203(91)90236-r.", "ArticleIdList": ["10.1016/0035-9203(91)90236-r", "1755059"]}, {"Citation": "Whitworth JA, Gilbert CE, Mabey DM, Maude GH, Morgan D, Taylor DW. Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone. Lancet. 1991;338(8775):1100\u20131103. doi: 10.1016/0140-6736(91)91963-u.", "ArticleIdList": ["10.1016/0140-6736(91)91963-u", "1682543"]}, {"Citation": "Whitworth JA, Morgan D, Maude GH, Luty AJ, Taylor DW. A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to four doses given at six-monthly intervals. Trans R Soc Trop Med Hyg. 1992;86(3):277\u2013280. doi: 10.1016/0035-9203(92)90308-y.", "ArticleIdList": ["10.1016/0035-9203(92)90308-y", "1412652"]}, {"Citation": "Whitworth JA, Luty AJ, Maude GH, Morgan D, Downham MD, Taylor DW. Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community. Trans R Soc Trop Med Hyg. 1992;86(3):281\u2013283. doi: 10.1016/0035-9203(92)90309-z.", "ArticleIdList": ["10.1016/0035-9203(92)90309-z", "1412653"]}, {"Citation": "Whitworth JA, Downham MD, Lahai G, Maude G. A community trial of ivermectin for onchocerciasis in Sierra Leone: compliance and parasitological profiles after three and a half years of intervention. Trop Med Int Health. 1996;1(1):52\u201358. doi: 10.1046/j.1365-3156.1996.d01-3.x.", "ArticleIdList": ["10.1046/j.1365-3156.1996.d01-3.x", "8673823"]}, {"Citation": "Whitworth JA, Maude GH, Downham MD. Clinical and parasitological responses after up to 6.5 years of ivermectin treatment for onchocerciasis. Trop Med Int Health. 1996;1(6):786\u201393. doi: 10.1111/j.1365-3156.1996.tb00111.x.", "ArticleIdList": ["10.1111/j.1365-3156.1996.tb00111.x", "8980590"]}, {"Citation": "White AT, Newland HS, Taylor HR, Erttmann KD, Larijani EK, Nara A, Aziz MA, D\u2019Anna SA, Williams PN, Greene BM. Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis. J Infect Dis. 1987;156(3):463\u2013470. doi: 10.1093/infdis/156.3.463.", "ArticleIdList": ["10.1093/infdis/156.3.463", "3302053"]}, {"Citation": "Wolstenholme AJ, Maclean MJ, Coates R, McCoy CJ, Reaves BJ. How do the macrocyclic lactones kill filarial nematode larvae? Invert Neurosci. 2016;16(3):7. doi: 10.1007/s10158-016-0190-7.", "ArticleIdList": ["10.1007/s10158-016-0190-7", "PMC5472989", "27279086"]}, {"Citation": "World Health Organisation (2000): Onchocerciasis (river blindness). The World Health Organization, Geneva. Fact Sheet No. 95."}, {"Citation": "World Health Organisation African Programme for Onchocerciasis Control: progress report, 2013\u20132014. Wkly Epidemiol Rec. 2014;89(49):551\u2013560.", "ArticleIdList": ["25485343"]}, {"Citation": "World Health Organisation (2020) Ending the neglect to attain the sustainable Development. A road map for neglected tropical diseases 2021\u20132030.\u00a0BYNC-SA 3.0 IGO,\u00a0World Health Organization"}, {"Citation": "World Health Organization . World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization; 2019."}, {"Citation": "Youssef MY, Sadaka HA, Eissa MM, el-Ariny AF. Topical application of ivermectin for humanectoparasites. Am J Trop Med Hyg. 1995;53(6):652\u20133. doi: 10.4269/ajtmh.1995.53.652.", "ArticleIdList": ["10.4269/ajtmh.1995.53.652", "8561270"]}, {"Citation": "Zahner H, Schares G (1993) Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Trop 52(4):221\u2013266. 10.1016/0001-706x(93)90010-9", "ArticleIdList": ["8094587"]}, {"Citation": "Zahner H, Taubert A, Harder A, Samson-Himmelstjerna GV. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int. J. Parasitol. 2001;31(13):1515\u20131522. doi: 10.1016/S0020-7519(01)00263-6.", "ArticleIdList": ["10.1016/S0020-7519(01)00263-6", "11595239"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "15"}, {"Year": "2021", "Month": "8", "Day": "30"}, {"Year": "2021", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "13", "Hour": "7", "Minute": "14"}, {"Year": "2021", "Month": "10", "Day": "13"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34642800", "PMC8599318", "10.1007/s00436-021-07307-4", "10.1007/s00436-021-07307-4"]}}], "PubmedBookArticle": []}